Filho AM, Laversanne M, Ferlay J, Colombet M, Piñeros M, Znaor A, Parkin DM, Soerjomataram I, Bray F. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336–46. https://doi.org/10.1002/ijc.35278.

Article  PubMed  CAS  Google Scholar 

Qian XJ, Wang JW, Liu JB, Yu X. The mediating role of miR-451/ETV4/MMP13 signaling axis on epithelialmesenchymal transition in promoting non-small cell lung cancer progression. Curr Mol Pharmacol. 2024;17:e210723218988. https://doi.org/10.2174/1874467217666230721123554.

Article  PubMed  Google Scholar 

Cai Y, Sheng Z, Dong Z, Wang J. EGFR inhibitor CL-387785 suppresses the progression of lung adenocarcinoma. Curr Mol Pharmacol. 2023;16(2):211–6. https://doi.org/10.2174/1874467215666220329212300.

Article  PubMed  CAS  Google Scholar 

Ullah A, Razzaq A, Alfaifi MY, Elbehairi SEI, Menaa F, Ullah N, Shehzadi S, Nawaz T, Iqbal H. Sanguinarine attenuates lung cancer progression via oxidative stress-induced cell apoptosis. Curr Mol Pharmacol. 2024;17: e18761429269383. https://doi.org/10.2174/0118761429269383231119062233.

Article  PubMed  CAS  Google Scholar 

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://doi.org/10.4065/83.5.584.

Article  PubMed  Google Scholar 

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54. https://doi.org/10.1038/nature25183.

Article  PubMed  CAS  Google Scholar 

Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2): 117. https://doi.org/10.1038/s41419-017-0063-y.

Article  PubMed  PubMed Central  Google Scholar 

Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 2007;57(3):253–60. https://doi.org/10.1016/j.lungcan.2007.03.012.

Article  PubMed  Google Scholar 

Xu S, Wang Y, Ren F, Li X, Ren D, Dong M, Chen G, Song Z, Chen J. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: an analysis of the cancer genome atlas data. Cancer Med. 2020;9(20):7686–94. https://doi.org/10.1002/cam4.3403.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Berger A, Hammerman P, Pugh T, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence M, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson B, Jänne P, Miller V, Pao W, Travis W, Pass H, Gabriel S, Lander E, Thomas R, Garraway L, Getz G, Meyerson M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–20. https://doi.org/10.1016/j.cell.2012.08.029.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn M-J, Felip E, Lee J-S, Hellmann MD, Hamid O, Goldman JW, Soria J-C, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824.

Article  PubMed  Google Scholar 

Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586–97. https://doi.org/10.1200/jco.21.01497.

Article  PubMed  CAS  Google Scholar 

Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–46. https://doi.org/10.1038/s41591-018-0007-9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–700. https://doi.org/10.1158/1078-0432.Ccr-19-0624.

Article  PubMed  CAS  Google Scholar 

Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22168661.

Article  PubMed  PubMed Central  Google Scholar 

Coulombe PA, Omary MB. ‘Hard’ and ‘soft’ principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol. 2002;14(1):110–22. https://doi.org/10.1016/s0955-0674(01)00301-5.

Article  PubMed  CAS  Google Scholar 

Magin TM, Vijayaraj P, Leube RE. Structural and regulatory functions of keratins. Exp Cell Res. 2007;313(10):2021–32. https://doi.org/10.1016/j.yexcr.2007.03.005.

Article  PubMed  CAS  Google Scholar 

Oshima RG, Baribault H, Caulín C. Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev. 1996;15(4):445–71. https://doi.org/10.1007/bf00054012.

Article  PubMed  CAS  Google Scholar 

Koehler DR, Hannam V, Belcastro R, Steer B, Wen Y, Post M, Downey G, Tanswell AK, Hu J. Targeting transgene expression for cystic fibrosis gene therapy. Mol Ther. 2001;4(1):58–65. https://doi.org/10.1006/mthe.2001.0412.

Article  PubMed  CAS  Google Scholar 

Zhang J, Hu S, Li Y. KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer. 2019. Biosci Rep. https://doi.org/10.1042/bsr20190884.

Fortier AM, Asselin E, Cadrin M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem. 2013;288(16):11555–71. https://doi.org/10.1074/jbc.M112.428920.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lai YC, Cheng CC, Lai YS, Liu YH. Cytokeratin 18-associated Histone 3 modulation in hepatocellular carcinoma: a mini review. Cancer Genomics Proteomics. 2017;14(4):219–23. https://doi.org/10.21873/cgp.20033.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40(5):403–39. https://doi.org/10.1046/j.1365-2559.2002.01387.x.

Article  PubMed  CAS  Google Scholar 

Wang PB, Chen Y, Ding GR, Du HW, Fan HY. Keratin 18 induces proliferation, migration, and invasion in gastric cancer via the MAPK signalling pathway. Clin Exp Pharmacol Physiol. 2021;48(1):147–56. https://doi.org/10.1111/1440-1681.13401.

Article  PubMed  CAS  Google Scholar 

Makino T, Yamasaki M, Takeno A, Shirakawa M, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Matsuura N, Mori M, Doki Y. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer. 2009;101(8):1298–306. https://doi.org/10.1038/sj.bjc.6605313.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003;39(6):769–74.

Article  PubMed  CAS  Google Scholar 

Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006;24(7):669–76. https://doi.org/10.1080/07357900600981307.

Article  PubMed